Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-10-02

Clinical Trial Update: Secondary Adjuvant Long Term Study With Arimidex [Phase 3]

View source ↗

Summary

Phase 3 long-term secondary adjuvant trial of Arimidex in breast cancer has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ARIMIDEX (anastrozole)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-10-02